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Abstract
Circulating tumor cells (CTCs) are important biomarkers of cancer progression and metastatic
potential. The rarity of CTCs in peripheral blood has driven the development of technologies to
isolate these tumor cells with high specificity; however, there are limited techniques available for
isolating target CTCs following enumeration. A strategy is described to capture and isolate viable
tumor cells from whole blood using an array of releasable microstructures termed micropallets.
Specific capture of nucleated cells or cells expressing epithelial cell adhesion molecules (EpCAM)
was achieved by functionalizing micropallet surfaces with either fibronectin, Matrigel or anti-
EpCAM antibody. Surface grafting of poly(acrylic acid) followed by covalent binding of protein
A/G enabled efficient capture of EpCAM antibody on the micropallet surface. MCF-7 cells, a
human breast adenocarcinoma, were retained on the array surface with 90 ± 8% efficiency when
using an anti-EpCAM-coated array. To demonstrate the efficiency of tumor cell retention on
micropallet arrays in the presence of blood, MCF-7 cells were mixed into whole blood and added
to small arrays (71 mm2) coated with fibronectin, Matrigel or anti-EpCAM. These approaches
achieved MCF-7 cell capture from ≤10 μL of whole blood with efficiencies greater than 85%.
Furthermore, MCF-7 cells intermixed with 1 mL blood and loaded onto large arrays (7171 mm2)
were captured with high efficiencies (≥97%), could be isolated from the array by a laser-based
approach and were demonstrated to yield a high rate of colony formation (≥85%) after removal
from the array. Clinical utility of this technology was shown through the capture, isolation and
successful culture of CTCs from the blood of mice engrafted with primary human pancreatic
tumors. Direct capture and isolation of living tumor cells from blood followed by analysis or
culture will be a valuable tool for cancer cell characterization.
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INTRODUCTION
Advances in clinical technologies have revealed the significance of low abundance
biomolecules or cells for monitoring patient health. Many studies have demonstrated the
utility of a non-invasive, “liquid” biopsy towards tracking disease progression or patient
health by quantifying low-concentration biomolecules in blood.1 Recent reports have
hypothesized that circulating tumor cells (CTCs) may provide valuable information
regarding the phenotype and metastatic behavior of an individual’s primary tumor.2,3
Efficient strategies to isolate these low abundance cells from peripheral blood may enable
novel clinical diagnostics as well as better understanding of cancer cell biology.
Many recent studies have sought to capture CTCs from the peripheral blood of patients or
animal models with cancer. Magnetic-activated cell sorting (MACS) and fluorescence-
activated cell sorting (FACS) are the oldest methods in use for isolating CTCs.3,4,
Unfortunately, MACS sorting is only capable of collecting CTCs based on their surface
markers, rarely provides 100% collection efficiency and is plagued by contaminating cells
such as lymphocytes and other nonspecifically captured cells. FACS is a commonly used
technology for retrieving pure cells from a heterogeneous population. The low abundance of
CTCs present in blood necessitates removal of erythrocytes prior to cell sorting and
generally suffers from loss of CTCs as well as reduced cell viability.5 Many of the methods
depending on surface expression of EpCAM may also suffer from poor CTC capture and
identification as a result of down regulation of EpCAM as the cells undergo an epithelial to
mesechymal evolution.6
The inefficiency of these technologies at isolating CTCs has spurred the development of a
multitude of new capture technologies to sort and analyze CTCs. Microfluidic based devices
for isolating CTCs enhance substrate-cell interactions by increasing the effective surface
area7 or by generating chaotic cell mixing to increase collisional contact with the surface.8
Some technologies have allowed collection of CTCs following capture by employing laser
pressure catapulting (LPC) or integrating a releasable antibody-substrate linker.9,18,21
Microfluidic devices have also achieved isolation of CTCs from blood by employing
enrichment within microwell arrays,10 fluidic switching11, dielectrophoresis12 and inertial
focusing.13 Size-selective microfilters have been developed in a variety of geometries to
effectively capture CTCs from whole blood.14 These size-based collection strategies are able
to capture and collect CTCs with excellent viability, however, they are unsuccessful at
capturing small CTCs and also suffer from clogging by lymphocytes when high blood
volumes are filtered. Though the tissue-cultured cells captured by the devices described
above retain a high level of proliferation; few reports have successfully demonstrated culture
of CTCs acquired from animal models and CTC culture from patient samples remains
extremely challenging due the fragile nature of these cells.4,15,16
Our lab has previously demonstrated the utility of arrays of releasable elements
microfabricated on glass substrates termed ‘micropallets’ for sorting single adherent cells.17
Micropallet technology has shown success at sorting single cells in a mixed cell population
with low reagent requirements, high post sorting yield and excellent viability. Additionally,
this platform has exhibited utility for isolating small numbers of target cells from mixed
populations especially when the target cells are present in low abundance.17
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Functionalization of the micropallet surfaces with extracellular matrices (ECM) or capture
antibodies has previously been reported to provide pre-enrichment of target cells prior to
sorting.18,19 In this report, the potential for using micropallet arrays to isolate tumor cells
directly from whole blood is examined. The capture efficiency was tested for MCF-7 cells
mixed into whole blood and loaded directly onto micropallet arrays functionalized with
fibronectin, Matrigel, or anti-EpCAM. Isolation of MCF-7 cells from whole blood followed
by laser-based release and culture was assessed along with the sorting of tumor cells directly
from the whole blood of mice bearing patient-derived pancreatic ductal adenocarcinoma.
MATERIALS AND METHODS
Micropallet functionalization
Micropallets were initially fabricated, as described in the supporting information, and
functionalized with fibronectin or Matrigel. Micropallet surfaces were treated with various
proteins to aid in cell capture and surface adhesion. Initially, micropallet arrays were
sterilized by rinsing with 95% ethanol and dried in a sterile hood. Excess ethanol was
removed with five rinses with phosphate buffered saline (PBS). For capture of adherent
cells, the top surfaces of the micropallets on the array were coated with 1 mL of 25 μg/mL
fibronectin in PBS for one hour at room temperature. For attachment of primary cells,
micropallets were incubated with 1% Matrigel (Matrix Growth Factor Reduced, BD
Biosciences, Franklin Lakes, NJ) in complete media for at least one hour at 37°C. Following
surface coating, the array was rinsed 5× with PBS. Alternatively, micropallet tops were
functionalized with anti-EpCAM antibody, as described in the supporting information
(Figure S1).
MCF-7 cell culture immediately before and after array-based isolation
MCF-7 cells (a human breast adenocarcinoma cell line) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with fetal bovine serum (FBS) (10%), L-
glutamine (584 mg L−1), penicillin (100 units mL−1) and streptomycin (100 μg ml−1) in a
37°C incubator with a 5% CO2 atmosphere. To ascertain the capture efficiency of adherent
cell lines from whole blood, MCF-7 cells were intermixed with sheep blood (BioChemed
Services, Winchester, VA). The sample was then mixed with 2 mL (small arrays) or 10 mL
(large arrays) of culture media and overlaid onto a fibronectin, Matrigel or anti-EpCAM
functionalized micropallet array. The array was then transferred to an incubator for at least 2
h to permit the adherent cells to settle and attach to the substrate. Isolated MCF-7 cells were
cultured in MCF-7-cell conditioned media.
Culture of primary human CTCs on arrays
Whole blood samples obtained from a PDX model of human pancreatic cancer were
cultured in a manner similar to the MCF-7 cells with the following exceptions20. Blood from
the mice was collected into a BD Microtainer® tube (BD Biosciences, Franklin Lakes, NJ)
and then diluted with 10 mL of pancreatic-cell conditioned media and incubated on the
micropallet arrays for 48 h in a 37°C incubator with a 5% CO2 atmosphere. Isolated
pancreatic CTCs were cultured in pancreatic-cell conditioned media, prepared as described
in the Supporting Information. Prior to cell analysis and separation, the arrays were rinsed
5–10 times with PBS to selectively remove the blood components. All animal studies were
approved by University of North Carolina at Chapel Hill Animal Care and Use Committee
and comply with Nation Institute of Health guidelines.
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Microscopy and micropallet isolation
Following immunostaining of CTCs, as described in the supporting information, screening
for CTCs over the large micropallet array was achieved with an MVX10 MacroView
microscope (Olympus, Center Valley, PA) and motorized stage (ProScan III motorized stage
system, H138A/C ProScan upright microscope stage, ProScan III motorized focus control,
Prior Scientific Inc., Rockland, MA) paired with an ORCA-Flash4.0 camera (Hamamatsu,
Bridgewater, NJ). Custom MATLAB software was used to analyze the acquired images in
addition to controlling the microscope, stage, and camera. Imaging small micropallet arrays
and micropallet release was performed on an inverted microscope (Eclipse TE300, Nikon,
Melville, NY) combined with a pulsed Nd:YAG laser (532 nm, 5 ns Polaris II laser, New
Wave Research, Fremont, CA). Released micropallets were then magnetically collected onto
a multiwell plate as described previously.21 Quantitative inaccuracies inherent to spiking
low numbers of MCF-7 for cell capture experiments were reduced by collecting the waste
generated during array rinsing and immunostaining into a petri dish. Imaging of captured
cells on the micropallet array and non-adherent MCF-7 cells collected into the waste
container provided the total MCF-7 cell count. The quotient of these values provided
accurate determination of MCF-7 cell capture efficiencies.
RESULTS AND DISCUSSION
Micropallet functionalization with anti-EpCAM
Anti-EpCAM antibodies are frequently utilized to capture CTCs since many epithelial-
derived tumors overexpress EpCAM.22 The possibility of coating micropallets by antibodies
was previously demonstrated by the physical absorption of IgG and IgE. The efficiency of
micropallet functionalization by physical absorption of anti-EpCAM was evaluated by
incubating micropallets with 10 ug/mL fluorescein labeled anti-EpCAM. No statistical
difference (two-sided t-test, t(6), p = 0.823) was observed between green fluorescence
images taken of 1002F photoresist coated with native anti-EpCAM (1005 ± 14) or
fluorescein labeled anti-EpCAM (954 ± 199). A higher density of potential linkage sites was
generated by grafting poly(acrylic acid) (PAA) onto the micropallet surface.23 Free amino
group proteins were then covalently linked to the grafted PAA through carbodiimide-
mediated amide formation. Effective binding of biomolecules to the micropallet tops was
demonstrated by covalently attaching fluorescein-labeled protein A. The average green
fluorescence of the fluorescein-protein A PAA-coated γFe2O3-1002F was 3351 ± 241,
statistically greater than that for native γFe2O3-1002F (638± 104) or native protein A-PAA-
coated γFe2O3-1002F (852 ± 9) (one-way ANOVA, F(2,6) = 98.86, p = 0.00003). For these
experiments, the reaction time for PAA grafting (12 h) was greatly reduced compared to that
reported previously (84 h)23 since the longer incubation times with cerium (IV) ammonium
nitrate (CAN) destroyed the virtual air walls between the micropallets. The virtual air walls
remained intact for the shorter duration reaction times although the PAA coating was
reduced relative to that of the 84-h reaction protocol (data not shown). The extent and
amount of anti-EpCAM antibody loaded onto the PAA grafted micropallets was measured
by incubating native anti-EpCAM or fluorescein-labeled anti-EpCAM on γFe2O3-1002F
grafted with protein A/G-coated PAA. A significant increase in the green fluorescence
intensity was observed for γFe2O3-1002F coated with fluorescein-anti-EpCAM with respect
to native anti-EpCAM or untreated γFe2O3-1002F; 2120 ± 185, 1725 ± 42 and 638 ± 104,
respectively (Figure 1) (one-way ANOVA, F(2,6) = 37.74, p = 0.0004). Functionalization of
anti-EpCAM by attachment to PAA-protein A/G exhibited the greatest surface density of
anti-EpCAM and so was employed for all subsequent experiments. Replacement of the
virtual air walls by a more rugged microstructure boundary such as poly(ethylene glycol)
(PEG) walls24 or polydimethylsiloxane (PDMS)25 may permit prolonged incubation with
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the CAN solution and likely improve the quantity of anti-EpCAM immobilization to the
array surfaces.
Cell capture on micropallets coated with anti-EpCAM
MCF-7 cells were utilized for initial assessment of cell capture by anti-EpCAM-coated
micropallets. MCF-7 cells are a breast cancer cell line that exhibits a high expression of
EpCAM antigen (509,500 molecules/cell), an order of magnitude higher than the EpCAM
expression observed in most CTCs.26 In triplicate experiments, 10,000 MCF-7 cells were
loaded onto the functionalized small micropallet arrays (12,769 micropallets) and the arrays
were incubated for 10 min (Figure S2). Nine images of the arrays were acquired covering a
fraction of the array’s total area (2430 micropallets) and the cells in each image were
counted. 1127 cells were identified (Fig. 2A). The arrays were then inverted and gently
agitated to remove unbound and loosely attached MCF-7 cells. The arrays were imaged
again and cells counted. 90 ± 8% (n = 3) of the cells remained attached to the arrays (Fig.
2B).
The specificity of cell capture was then determined by repeating the experiment with HeLa
cells (n = 3 arrays, 2430 micropallets imaged, 988 total cells initially identified) (Fig. 2C).
HeLa cells were used as a control since these cells express little to no EpCAM.27 Only 12 ±
5% of the HeLa cells (118 total cells) were retained following inversion and agitation of the
array (Fig. 2D). The significantly reduced collection of HeLa cells relative to MCF-7 cells
suggested that the mechanism of cell capture for these short incubation times was primarily
due to antibody-antigen binding as opposed to non-specific cell adhesion to the substrate
(two-sided t-test, t(6), p = 0.0001).
The non-specific capture of cells was examined by monitoring the attachment of MCF-7
cells on grafted arrays not coated with anti-EpCAM, i.e. micropallets grafted with PAA and
functionalized with only Protein A/G. Following a 10 min incubation period and array
inversion, 21 ± 11% of the MCF-7 cells remained adhered to the micropallets (316 cells).
Repeating the control experiment with a prolonged incubation period of 2 h drastically
enhanced the retention of MCF-7 to 87 ± 4% (1456 adhered cells). These significantly
different results imply the initial mechanism of cell attachment to anti-EpCAM
functionalized micropallets is antibody-antigen binding (two-sided t-test, t(6), p = 0.0006)
rather through an integrin-mediated mechanism. Enrichment of tumor cells by antibody-
based binding ensures collection of the majority of antigen-expressing CTCs from a sample.
In future studies, micropallet surfaces could be functionalized with other CTC binding
molecules to capture cells with minimal EpCAM expression.6
MCF-7 cell capture from whole blood with micropallets
Enrichment of all or only viable CTCs has previously been demonstrated by selective
capture of these cells onto an antibody7 or extracellular matrix28 coated substrate,
respectively. Each capture strategy has its own advantages. For example, the majority of
CTCs in circulation are either apoptotic or non-proliferating and thus may not be able to
spontaneously adhere to surfaces using integrins and other ECM-binding molecules.29 These
cells may need to be passively captured onto surfaces using high affinity moieties such as
antibodies in order to provide a total CTC cell count. However, these selective techniques
could potentially overlook capture of CTCs with unknown surface markers.
CTC enrichment directly from whole blood was examined by testing capture by micropallets
with three different surface functionalizations: anti-EpCAM, fibronectin or Matrigel. As a
proof-of-principle, approximately 100 MCF-7 cells were mixed into 1, 10 or 100 μL of
whole blood which was then diluted with cell culture media (2 mL) and then loaded onto
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small arrays, in triplicate experiments (Figure 3, Table 1). For ease of analysis, arrays
comprising 12,769 elements were utilized in place of the larger micropallet arrays (Figure
S2). The quantity of blood added to the smaller arrays was equivalent (blood volume/array
surface area) to adding 0.1, 1 and 10 mL of whole blood to the larger micropallet arrays used
below. The arrays were placed in an incubator for a designated incubation period designed
to capture a maximal number of target cells; 2-h for anti-EpCAM micropallets and 8-h for
fibronectin and Matrigel-coated micropallets. These longer times were employed to enable
the CTCs to migrate through the multilayered red blood cells to reach the pallet surface.
Since capture of MCF-7 cells on negatively charged surfaces required much longer times
than that for antibody-coated surfaces, longer incubation times were employed for the
extracellular matrix-based capture.
Immediately prior to imaging, the arrays were rinsed with PBS to remove unattached cells.
The efficiency of erythrocyte and lymphocyte removal was dependent on the number of
rinses applied to the array. After 10 rinses, < 21000 erythrocytes and 220 lymphocytes
remained on the arrays with the different tailored surfaces (Table 1). This is approximately 1
erythrocyte and 0.01 lymphocytes per micropallet, adequate enough to allow quality
imaging of the micropallets (Figure 3). Of the MCF-7 cells mixed into 1, 10 or 100 μL
whole blood, ≥85%, ≥87%, and >38% of the MCF-7 cells attached to the micropallets,
respectively (Table 1). Interestingly, the capture efficiency of MCF-7 cells intermixed with
blood was not significantly different for the anti-EpCAM, fibronectin or Matrigel-coated
arrays despite contrasting capture mechanisms (one-way ANOVA, [1 μL blood] F(2,6) =
2.275, p = 0.184, [10 μL blood] F(2,6) = 1.076, p = 0.399, [100 μL blood] F(2,6) = 0.979, p
= 0.429). The maximal capture efficiency of 96% corresponded to the percentage of living
cells within a typical MCF-7 culture since the rapidly growing cells exhibit a high
percentage of senescent cells (5%). The low capture efficiency of MCF-7 cells when mixed
into 100 μL whole blood and incubated on the array under static conditions was likely due to
the dense layer of erythrocytes on the array. When the volume of blood cells was
sufficiently dilute, MCF-7 cells were able to encounter the array surface and adhere to the
micropallets. Efficient CTC isolation from clinically relevant volumes of blood could
potentially be achieved through lysis of erythrocytes or by use of larger arrays, as described
below.
Isolation and expansion of MCF-7 cells captured from whole blood
A large array (10.1 × 7.1 cm, 1.3 million micropallets) was employed for determining the
utility of micropallets for isolating CTCs directly from clinically relevant volumes of whole
blood. Capture efficiencies were examined by mixing 1, 10 and 100 MCF-7 cells into 1 mL
of whole blood diluted with 10 mL media and then incubated on the arrays. Since all surface
coatings captured MCF-7 cells equally, we only employed fibronectin-coated micropallet
arrays due to its ease of functionalization and low cost. Following removal of non-adherent
cells by rinsing with PBS, MCF-7 cells were stained with Hoechst 33342 and fluorescein-
labeled anti-CD45 and Alexa Fluor 647-labeled anti-EpCAM antibody. MCF-7 cells
(Hoechst 33342+/CD45-/EpCAM+) were enumerated by imaging the arrays with an
automated wide field microscope (Fig. 4A). A customized MATLAB image analysis
program identified 2, 10 and 96 MCF-7 cells from the arrays loaded with the blood samples
expected to have 1, 10 and 100 cells, respectively. The micropallet arrays enabled the
systematic visualization of cells attached to the array over an extended time-frame prior to
sorting. Isolation of MCF-7 cells from the array was achieved by laser-based release of 2, 10
and 20 MCF-7-containing micropallets followed by collection using a magnetic field, as
described previously (Fig. 4B).21 After a 7-d incubation; 2 of 2, 10 of 10 and 17 of 20 of the
collected cells on micropallets formed colonies demonstrating that the cells remained viable
following mixing and incubation with the blood sample. All cell colonies were Hoechst
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33342+, EpCAM+, and CD45− indicating that the cells retained their initial phenotype (Fig.
4C).
Isolation of CTCs from patient-derived xenograft (PDX) mouse models
To further validate the efficacy of micropallet technology and demonstrate possible clinical
significance, micropallets were employed to isolate CTCs from the blood of mice engrafted
with human pancreatic ductal adenocarcinoma (PDAC) tumors (Fig. 5A). PDX mice have
previously been shown to be excellent mimics of human disease and fully recapitulate the
parental human tumor morphology and growth characteristics including subsequent
extravasation and metastases formation.30 The small volumes of blood (<1 mL) and CTCs
(<100) in these mice make analysis and culture of CTCs from individual mice by typical
low-efficiency techniques ineffective. Whole blood collected from a PDX mouse (0.6 – 1.0
mL) was mixed with pancreatic-cell conditioned media (10 mL) supplemented with insulin
growth factor (IGF) and epithelial growth factor (EGF), and then incubated for 48 h on
separate large micropallet arrays coated with Matrigel (n = 3). Matrigel, pancreatic-cell
condition media and longer incubation periods were used to improve the chances of
successfully culturing CTCs on the micropallets. Non-adherent cells were then washed from
the array with PBS. Incubation of the arrays with blood for 48 h increased lymphocyte
capture 4.4-fold relative to the 8-hour incubation time. The longer incubation did not alter
the numbers of captured erythrocytes. Arrays were stained with Hoechst 33342, fluorescein-
anti-CD45 and Alexa Fluor 647-anti-Cytokeratin antibodies and CTCs enumerated by
imaging as described above. With this approach, 13 ± 6 cells identified on the micropallets
were Hoechst 33342+/CD45−/Cytokeratin+. This CTC count is similar to the value of 23 ± 7
CTCs per mL blood obtained from the same PDX model by Soper and colleagues using a
microfluidic device (two-sided t-test, t(7), p = 0.1048).31
In addition to CTC enumeration, micropallet technology offers the capability of subsequent
isolation and culture of viable CTCs. EpCAM has previously been demonstrated as being
highly expressed in pancreatic adenocarcinoma, thus making it an excellent biomarker for
viable detection of pancreatic adenocarcinoma-derived CTCs in contrast to the Cytokeratin
which requires cell fixation.32 CTCs were captured from 0.7 mL PDX mouse blood and
immunostained for EpCAM and CD45. Ten cells were identified on the arrays as being
EpCAM+/Hoechst 33342+/CD45− (Fig. B,C). The ten micropallets carrying CTCs were then
released from the array and magnetically collected onto a multiwell plate coated with
Matrigel. The cells remained adherent to the micropallets after isolation as observed by
brightfield and fluorescence microscopy (Fig. 5D,E). Two of the ten cells isolated were
viable as evidenced by their ability to form a cell colony following 7 days culture in
pancreatic-cell conditioned media supplemented with IGF and EGF (Fig. 5F,G). The
successful ex vivo colony formation from a minute quantity of CTCs was a result of the
minimal sample processing and cellular manipulation afforded by micropallet technology.
Successful culture of CTCs directly from the blood of xenograft mice models of human
pancreatic adenocarcinoma will enable a better understanding of the biology of CTCs as
well as the diversity in CTC properties.
CONCLUSIONS
This current work demonstrates the capability of tumor cell isolation directly from whole
blood using the micropallet technology. Micropallets functionalized with either fibronectin
or anti-EpCAM were able to efficiently capture MCF-7 cells from whole blood with high
efficiency (≥85%) and very minimal sample processing. In addition to capture and
enumeration, MCF-7 cells could be isolated and cultured with a high success rate of colony
formation (≥85%). Furthermore, it was to capture, isolate and subsequently culture
Gach et al. Page 7













pancreatic CTCs derived from PDX mice. Technologies capable of isolating and culturing
primary CTCs could play an essential role in our understanding of cancer metastasis as well
as in drug development to prevent these events. While static conditions lead to low capture
efficiencies with larger volumes of blood, micropallet bases with high aspect ratios and
surfaces grafted with anti-EpCAM could be incorporated into a microfluidic channel
increasing the volume of blood processed by these arrays. A combined micropallet-
microfluidic device might take advantage of the high throughput cell capture rates offered
by microfluidics and the gentle release of micropallets holding captured CTCs. Additionally,
previous successes of micropallets for sampling of cell colonies could be adapted to provide
minimally invasive colony sampling and analysis over the lifespan of the developing tumor
with results compared to tumor growth in vivo.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• CTCs were captured from whole blood on an array.
• The array elements were releasable enabling viable CTC isolation.
• Greater than 85% of tumor cells were captured from 1 mL of whole blood.
• CTCs were captured and cultured from a xenografted human pancreatic
adenocarcinoma.
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anti-EpCAM functionalization of micropallets. Brightfield image of micropallets (A) and
fluorescence image of native micropallets (B), fluorescein-labeled anti-EpCAM physically
absorbed to micropallets (C) and fluorescein-labeled anti-EpCAM attached to micropallets
using PAA-protein A/G (D).
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Selective cell capture on anti-EpCAM functionalized micropallets. MCF-7 cells on an anti-
EpCAM functionalized micropallet array before (A) and after rinsing (B). HeLa cells on an
anti-EpCAM functionalized micropallet array before (C) and after rinsing (D).
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Capture of MCF-7 cells from peripherial blood. Brightfield (A) and fluorescence images (B)
of fibronectin-coated arrays overlaid with 10 μL whole blood containing MCF-7 cells
stained with fluorescein-labeled anti-EpCAM prior to removal of the blood. Brightfield (C)
and fluorescence images (D) of the same array in A and B after sequential PBS rinses.
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MCF-7 cell isolation from peripherial blood and culture. Brightfield (left column) and
fluorecence (right 3 columns) micrographs of a single MCF-7 cell identified after addition of
1 mL of whole blood to a large micropallet array (A). The cell in panel A immediately after
micropallet release from the array and collection (B) and after 7 days of culture (C). The
DNA of MCF-7 cells was stained with Hoechst 33342 nuclear stain (second column from
left, blue). The cells were aso stained with Alexa Fluor 647-anti-EpCAM antibody (far right
column, red) and fluorescein-anti-CD45 (second column from right, green). Scale bars
represent 50 μm.
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Isolation and culture of CTCs from peripheral blood samples from a pancreatic cancer
patient-derived xenograft. (A) Schematic of the collection of whole blood from a mouse
implantated with a patient tumor (i), loading of blood onto micropallet arrays (ii), removal
of non-adherent blood cells and immunostaining (iii), selective release and collection of
target micropallets (iv) and CTC culture (v). (B,C) Whole blood was incubated on the array
for 2 days and then the array washed to removed nonadherent cells. Shown are a brightfield
(B) and a composite fluorescence image (Hoeschst 33342, anti-CD45, anti-EpCAM) (C) of
a cell on the array. (D,E) A micropallet with a CTC was isolated from the array and
immediately imaged as in panels B and C. The white dot below the CTC in E represents a
fixed camera pixel. (F,G) A collected micropallet with a CTC was cultured for 7 d,
immunostained and imaged as in panels B and C. Scale bars represent 50 μm.
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